NCT04373148 is a clinical trial of There is no intervention in Coronavirus, sponsored by Stanford University.

Who is sponsoring NCT04373148?

NCT04373148 is sponsored by Stanford University.

What drugs are being tested in NCT04373148?

Interventions in NCT04373148: There is no intervention.

What condition does NCT04373148 study?

NCT04373148 studies Coronavirus.

Is NCT04373148 still recruiting?

NCT04373148 is currently completed. Last updated 15 June 2022.

Last reviewed 2022-06-15 · How we verify

NCT04373148

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19

Completed Last updated 15 June 2022

What this trial tests

trial testing There is no intervention in Coronavirus in 316 participants. Completed in 31 May 2022.

Timeline

8 April 2020

Primary endpoint
31 May 2022

31 May 2022

Quick facts

Lead sponsor	Stanford University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	316
Start date	8 April 2020
Primary completion	31 May 2022
Estimated completion	31 May 2022
Sites	2 locations across United States

Drugs / interventions tested

There is no intervention — full drug profile →

Conditions studied

Coronavirus — all drugs for Coronavirus →

Sponsor

Stanford University

Who can join

2 and older, any sex, with Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test over time immunity to SARS-CoV-2, a recently identified coronavirus responsible for the 2019 world-wide pneumonia outbreak known as COVID-19. Adults and children diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

KIR<sup>+</sup>CD8<sup>+</sup> T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19.
Li J, Zaslavsky M, Su Y, Guo J, et al · · 2022 · cited 225× · PMID 35258337 · DOI 10.1126/science.abi9591
Gut Microbiota Dysbiosis-Immune Hyperresponse-Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches.
Ferreira C, Viana SD, Reis F. · · 2020 · cited 44× · PMID 33019592 · DOI 10.3390/microorganisms8101514
Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndrome.
Jia X, Cao S, Lee AS, Manohar M, et al · · 2022 · cited 33× · PMID 35801588 · DOI 10.1172/jci.insight.156713
Therapeutic Peptides: Recent Advances in Discovery, Synthesis, and Clinical Translation.
Zheng B, Wang X, Guo M, Tzeng CM. · · 2025 · cited 23× · PMID 40507941 · DOI 10.3390/ijms26115131
Single cell multi-omic analysis identifies key genes differentially expressed in innate lymphoid cells from COVID-19 patients.
Kaushik A, Chang I, Han X, He Z, et al · · 2024 · cited 5× · PMID 39026668 · DOI 10.3389/fimmu.2024.1374828

Verify or expand the search:

Other trials of There is no intervention

Trials testing the same drug.

NCT07401420 — Life Sustaining Treatments in Critically Ill Children · not yet recruiting
NCT06343675 — Systematic Health-promoting Work Environment Management in Dentistry · completed
NCT06517238 — A New Digital Communication Tool Between Dentist and Orthodontist to Improve Dental Prevention · recruiting
NCT06301217 — Are Axioscapular Muscles Activity and Cervical Curvature Associated With Disability in Neck Pain · unknown
NCT05981599 — Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease · unknown

Other recruiting trials for Coronavirus

Currently open trials in the same condition.

NCT04772170 — Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies · recruiting
NCT05868239 — Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study · NA · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04373148 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 15 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04373148.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing